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Abstract: Approximately 5%–10% of asthmatics suffer from severe asthma. New biological 
treatments represent a great opportunity to reduce asthma burden and to improve asthma patients’ 
lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ 
monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20–50 minutes every 
4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/μL or more in 
their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving 
the quality of life and lung function are clear, but further research is needed to determine the 
best biological compound for a specific cluster of patients. Research data have shown that in 
patients who were expressing other clinical features of eosinophilic inflammation over asthma 
(rhinosinusitis and nasal polyposis), the clinical benefit of reslizumab was greater. Furthermore, it 
has also been observed that in patients with unsatisfactory response to mepolizumab, reslizumab 
is able to significantly improve the clinical and biological parameters. The aim of personalized 
medicine is to provide the right drug to the right patient at the right dose at the right moment. 
The biological treatments that were developed to modify specific pathological pathways not only 
provide us with the tools for the management of asthma patients but also clarify the biological 
mechanisms involved in its pathogenesis.
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Reslizumab in the context of personalized medicine 
of severe asthma 
According to the current estimates, asthma is globally the most prevalent chronic 
respiratory disease affecting more than 358 million people and its incidence is still 
increasing.1 The introduction of international guidelines (Global Initiative for Asthma, 
GINA)2 for the management of asthma in 1993 and their implementation into clinical 
practice have not only significantly altered the burden of the disease but also revealed 
the areas of inadequate treatment control and unmet needs. The significant heterogene-
ity of asthma leads to the identification of various asthma phenotypes. The problem 
of severe asthma emerged more clearly when the management strategy introduced the 
focus on asthma control.3 Severe asthma is defined as “asthma which requires treat-
ment with high dose inhaled corticosteroids (ICSs) plus a second controller (and/or 
systemic corticosteroids) to prevent it from becoming “uncontrolled” or which remains 
“uncontrolled” despite this therapy”.4 The prevalence of severe asthma is reported to 
be around 5% with high rate of poor control (>50% of patients) with a significantly 
higher risk of exacerbations (risk ratio 2.59) and a low level of health-related quality 
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of life (HRQoL).5 Although the prevalence of severe asthma 
is low, the burden of the disease on the patient, family, health 
care system, and society is disproportionally high, accounting 
for up to 30% of all costs incurred by all asthmatic patients.6 
Solving the problem of severe asthma is complicated due to 
the fact that it is a heterogeneous condition presenting with 
different phenotypes that are based on distinct endotypes.4 
Various studies have identified several phenotypes of severe 
asthma primarily based on a different set of input parameters, 
but ~50% of severe asthma patients have elevated eosinophil 
levels and certain level of resistance to corticosteroid treat-
ment. Both these characteristics are associated with increased 
burden (lower rate of control, higher rate of exacerbations, 
and adverse events) and costs of asthma (>double).7 Based on 
this fact, a corticosteroid sparing strategy that would down-
regulate the high level of eosinophils could produce benefits 
on disease control and reduce its burden. Both the innate and 
adaptive immunity pathways of type-2 airway inflammation 
(“Th2-high asthma” phenotype) are involved with many 
cell types and signaling molecules.8 In severe eosinophilic 
asthma, interleukin-5 (IL-5) has been found to be one of the 
major players in the recruitment of eosinophils; therefore, 
biological drug–targeting strategies have been developed by 
using humanized monoclonal antibodies (hmAbs). Of the two 
hmAbs that have been created, one binds to IL-5 preventing 
from binding to its receptor (mepolizumab and reslizumab) 
and the other (benralizumab) binds to IL-5 alpha chain 
receptor (IL-5Rα). Both mepolizumab and reslizumab have 
been shown to be clinically effective, allowing for a precision 
medicine approach targeting a specific pathway.9 Nowadays, 
the use of novel research technologies (genomics, transcrip-
tomics, proteomics, and metabolomics) allows us to define 
heterogeneity among patient subgroups and among individual 
patients on the basis of a specific pathophysiological pat-
terns, networks of effector cells, and signaling molecules, 
allowing us to specifically target these pathways. Although 
it might seem that precision and personalized medicine are 
synonyms, this is not the case. Unlike precision medicine 
that targets specific endotypes or major endotypes behind 
specific phenotypes in a (sub)group of patients, personalized 
medicine is an individually tailored treatment. Meanwhile, 
specific markers like blood and sputum eosinophils, fraction 
of exhaled nitrous oxide, periostin, and even recent omics 
approaches allow only a precision medicine approach.10,11 
As with other medicines, an individual response to differ-
ent drugs of the same class is to be expected. Strategies to 
decode the pathophysiological mechanisms behind the spe-
cific phenotype in individual patients using the newest omics 
sciences will allow a personalized approach to individual 
patients.12,13 However, to develop such strategies, we would 
need the records of patients who were treated with specific 
biological agents, like reslizumab, supported with biobanks 
and high-throughput omics technologies.
Biological properties of anti-IL-5 
molecules 
Reslizumab is a humanized IgG4/κ mAb produced by means 
of a synthetic process based on recombinant technology, 
which allows the integration of the rat antigen recognition 
sites for human IL-5 to a human IgG4.14–16 The antibody can 
bind free IL-5 molecules (dissociation constant = 81 pM; 
association constant of 4.9 × 105 per M/s). This bonding 
prevents IL-5 from linking to its receptor.16–19 It is matter of 
fact that reslizumab at a concentration of 0.5 nM inhibits IL-5 
binding by 50% and at 45 nM inhibits IL-5-induced prolifera-
tion by 50%. Reslizumab has been tested in animal models 
featuring eosinophilic inflammation,20 such as allergic mice 
and ascaris-responsive monkeys. The effect of the drug lasted 
for 6 months after administration in monkeys, thereby reduc-
ing the ascaris challenge-induced eosinophilia by 75%.21 In 
ovalbumin-sensitized guinea pig model, reslizumab (0.03 mg/
kg and 1 mg/kg) administered 2 hours before the specific chal-
lenge reduced eosinophilia, airway hyperreactivity, and bron-
choconstriction. In ovalbumin-sensitized rabbits, reslizumab 
decreased the eosinophil influx into the skin without impacting 
the overall number of cells in the skin.16 The aforementioned 
data justify the in vivo investigation that demonstrated that 
reslizumab reduces airway hyperresponsiveness and inhibits 
the influx of eosinophils into the lungs. For example, in ani-
mals exposed to an agent that increases the eosinophil count 
to 298,000 cells/mL, a 1 mg/kg dose reduced eosinophil in 
the bronchoalveolar lavage counts to 108,000 cells/mL.16 
Furthermore, in the Phase II Res-5-0010 study, reslizumab sig-
nificantly lowered the active airway eosinophilic inflammation 
by reducing the sputum eosinophil count by 95% compared 
with a 39% reduction for placebo.22 At present, the anti-IL-5 
mAb families also include mepolizumab, while benralizumab 
binds to the surface of IL-5 receptor. Mepolizumab, unlike 
reslizumab, is a humanized IgG1. Mepolizumab is composed 
of 4 light and heavy chains linked by a disulfide bridge. The 
antibody binds with high-specificity and -affinity IL-523 (IC
50
 
< 1 nM; K
d
 = 4.2 pM) and avoids binding to IL-5Rα.24,25 
Both mepolizumab and reslizumab bind to epitopes within 
the IL-5Rα-binding domain, while mAbs interacting with 
IL-5βc domain are currently not available, although this may 
represent a potential target.
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Functional and biological results 
from pivotal trials
Reslizumab has been recently approved for the treatment of 
severe eosinophilic asthma. This is due to its safety profile 
and efficacy. The first study that showed the efficacy of the 
drug in reducing eosinophils in asthmatics was conducted 
by Kips et al.26 The pilot investigation was carried out in a 
small number of subjects (n = 32) who were suffering from 
severe persistent asthma despite high-dose ICSs or systemic 
corticosteroids and they were treated with placebo or resli-
zumab intravenously (IV). No significant effect on eosinophil 
counts was observed in patients treated with lower doses, 
whereas a sustained response was observed in those treated 
with the highest dose. Interestingly, there were no significant 
differences in lung function or symptom scores among the 
study groups. These disappointing findings can be reasonably 
explained by the “small and not powered” study population 
and by the lack of preselection of patients with eosinophilia.
To overcome this issue, a multicenter, randomized, dou-
ble-blind, placebo-controlled study was designed to explore 
the effects of reslizumab versus placebo in poorly controlled 
adult asthmatics with induced sputum eosinophils of 3% or 
more.22 As expected, patients who received reslizumab had 
a significant decrease in sputum eosinophils. An improve-
ment from baseline in forced expiratory volume in 1 second 
(FEV1) was found in the reslizumab group compared with 
placebo. In addition, a trend for improvement in asthma 
control and reduction in exacerbation rates was shown in 
the active group, although it was not statistically significant.
Two subsequent studies had the merit of including blood 
eosinophil count instead of sputum eosinophils to define 
eosinophilic asthma, thus limiting the intrinsic variability due 
to the difficulties in collecting sputum from severe asthmatics 
and lack of reproducible findings. Two other trials assessed 
the efficacy of reslizumab in severe asthmatics.27 A total of 
953 patients received reslizumab at a dose of 3 mg/kg or 
placebo IV every 4 weeks (Q4W) for a total of 13 doses. 
Patients in the active group showed early improvements in 
lung function and in symptoms, as well as a reduction in 
asthma exacerbations compared with placebo. Corren et al28 
investigated the efficacy of reslizumab in a cohort of 496 
uncontrolled asthmatic subjects with a wide range of blood 
eosinophilic concentrations. The efficacy of reslizumab in 
terms of improvements in pulmonary function, as well as in 
terms of Asthma Control Questionnaire (ACQ) scores and 
rescue inhaler use, was detected only in subgroup analyses 
in subjects with eosinophil counts >400/L.
Patient-reported outcomes (PROs) 
results from pivotal trials
PROs – “any report coming from patients about a health 
condition that comes directly from the patient, without inter-
pretation of the patient’s response by a clinician or anyone 
else”29 – allow to capture a patient’s subjective perspective 
on the effectiveness of a treatment. As such, PROs provide 
the possibility to include the input coming from patients in 
assessing the impact of a treatment and may personalize 
the treatment decision-making process.30 All the registered 
studies evaluating the efficacy and safety of reslizumab in 
asthma patients include the assessment of PROs as primary22 
or secondary outcomes.29–31 In the study by Castro et al,22 the 
primary end point was the change of asthma control (assessed 
by ACQ-7)32 in patients who were treated with reslizumab 
or placebo for 15 weeks. The mean change in ACQ-7 score 
from baseline to the study end was modest and did not achieve 
statistical significance (−0.7 in the reslizumab group and −0.3 
in the placebo group, p = 0.0541). A subgroup analysis of 
patients with comorbid nasal polyps detected a significantly 
greater improvement in ACQ-7 scores in the active group than 
in placebo group (−1.0 vs −0.1, p = 0.0119). The minimal 
important difference (MID) of 0.5,33 which represents the 
smallest change perceived as beneficial by patients,34 was 
achieved in 59% of patients in the reslizumab group and 
in 40% of patients in the placebo group (odds ratio: 2.06, 
p = 0.0973). The results of the two parallel studies described 
by Hart et al25 showed that the significant effect of reslizumab 
on the primary outcome (frequency of asthma exacerbations) 
moves in parallel with the effect on PROs. As a matter of 
fact, the scores of Asthma Quality of Life Questionnaire 
(AQLQ),35 ACQ-7,32 and Asthma Symptom Utility Index 
(ASUI)36 show a significantly greater improvement (p < 0.05) 
in the active group compared with placebo. Moreover, com-
pared to placebo group, a higher percentage of patients in 
the reslizumab group reached the MID37 in AQLQ (study 1: 
74% vs 65%, p = 0.03; study 2: 73% vs 62%, p = 0.02) and 
in ACQ-7 (study 1: 76% vs 63%, p = 0.0002; study 2: 77% vs 
61%, p = 0.0002). Corren et al28 showed that the mean change 
of ACQ-7 score was modest from baseline to the end of the 
study (week 16) and the differences between reslizumab 
and placebo groups did not reach statistical significance. 
However, the percentage of patients who reached the MID 
was significantly higher with reslizumab than with placebo 
(71% vs 57%, p = 0.01). Moreover, a secondary analysis in 
the subgroup of patients with a blood eosinophil count of 
≥400 cells/mL detected a small but significant  improvement 
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with reslizumab treatment compared with placebo treat-
ment (0.272 vs 0.002, p = 0.0436), corresponding to the 
improvement in FEV1. Both reslizumab 0.3 mg/kg and 3.0 
mg/kg29 significantly improved asthma control (ACQ-7) 
and frequency and severity of symptoms (ASUI) compared 
with placebo. Both the tools detected a greater magnitude 
of improvement in the group treated with reslizumab 3 mg/
kg. At the end of the study, MID of ACQ-7 was reached by a 
similar percentage of patients in the reslizumab and placebo 
groups, without any significant difference among the groups. 
Improvements in AQLQ scores versus placebo were observed 
for reslizumab 3 mg/kg (1.138 vs 0.779, p = 0.0241) but not 
for reslizumab 0.3 mg/kg (1.057 vs 0.779, p = 0.0822). A 
greater proportion of patients in the active groups compared 
to placebo group achieved the MID of AQLQ at the study end. 
The difference versus placebo was significant for reslizumab 
3 mg/kg (64% vs 48%, p = 0.0189) but not for reslizumab 
0.3 mg/kg (59% vs 48%, p > 0.05).
Placement of reslizumab in 
biological treatment of asthma
Reslizumab administered by IV perfusion has demonstrated 
a notable effect, compared to placebo, in reducing exacerba-
tions and in triggering significant improvements in pulmonary 
function in adult patients with severe eosinophilic asthma 
(baseline levels of eosinophils ≥400 cells/μL) that remains 
inadequately controlled despite being treated with high doses 
of ICS + long-acting beta-agonists and/or oral corticoids.22,27–29 
It should be noted that clinical trials on mepolizumab and 
reslizumab have produced similar results, but the studied 
populations have never been exactly the same. However, in the 
absence of any direct comparisons, it is impossible to estab-
lish the differences (or otherwise) between these two drugs, 
although reslizumab, unlike subcutaneous mepolizumab, 
could be limited by the need for IV administration but could 
provide a greater sense of care to the patient. Moreover, no 
specific studies have confirmed the effect of reslizumab on 
reducing the use of oral corticoids, whereas these data are 
available in the case of mepolizumab.38,39 These limitations 
must be considered before selecting treatment. More recently, 
however, a study investigated 10 prednisone-dependent 
asthmatics (blood eosinophils >300 cells/μL and sputum 
eosinophils >3%) who had previously received mepolizumab 
(100 mg subcutaneous dose Q4W) for at least 1 year and two 
infusions of placebo (Q4W) followed by 4 infusions of 3 mg/
kg reslizumab Q4W, in a single-blind, placebo-controlled 
sequential trial.40 The authors found that the weight-adjusted 
IV reslizumab was superior to the fixed-dose subcutaneous 
mepolizumab in attenuating eosinophilia. Attenuation of both 
local and systemic eosinophilia was associated with statisti-
cally significant improvements in asthma control and FEV1. 
Reslizumab could, therefore, be also used as an alternative for 
those patients who show no improvement with mepolizumab. 
In 2016, Froidure et al41 created a decision chart to aid the 
selection of appropriate biological treatment, based on the lev-
els of IgE and eosinophilia in the blood, but there is currently 
some controversy concerning the mAb that should be first 
used in case of allergic and eosinophilic asthma. Some authors 
have suggested that omalizumab should be used as the first 
option in patients with an allergic phenotype, regardless of the 
levels of eosinophils in the peripheral blood, with anti-IL-5 
as an alternative for allergic patients with blood eosinophilia 
in whom omalizumab treatment has failed.42 A recently pub-
lished post-hoc analysis43 of two 52-week placebo-controlled 
trials of reslizumab IV 3 mg/kg every 4 weeks in patients with 
uncontrolled asthma has compared the results for pulmonary 
function and exacerbations in patients with late-onset asthma 
to those with early onset asthma. This analysis showed that 
reslizumab produced greater improvements in lung function 
and larger reductions in asthma exacerbations in patients 
with late-onset asthma compared to those with early onset 
asthma. This could be an important consideration when 
deciding on biological treatment. Although no studies have 
been undertaken to compare such findings with the efficacy of 
omalizumab in patients with late-onset asthma, the results of 
the aforementioned analysis suggest that the use of anti-IL-5 
could be posited as a first option for allergic and eosinophilic 
patients with late-onset asthma. An algorithm for treatment 
has been created based on phenotypes by Domingo42 and 
Alvarez et al,44 but the value of these approaches needs to be 
explored in real life. Other factors that possibly need to be 
considered before choosing a mAb are asthma severity and 
pulmonary function. A recent study has published pooled data 
from duplicate, Phase III, reslizumab versus placebo trials, in 
which patients were categorized according to severity (Steps 
4 and 5 of the GINA guidelines). This study showed that, 
compared with placebo, reslizumab has increased FEV1 in 
Step 4 and Step 5 groups by 103 mL (52–154 mL) and 237 mL 
(68–407 mL), respectively. Additionally, reslizumab reduced 
exacerbation rates by 53% (0.36–0.62) and 72% (0.15–0.52) 
in Step 4 and Step 5 groups, respectively.45 Furthermore, 
reslizumab has been shown to improve nasal polyposis in 
patients with severe asthma.46 Some meta-analyses have also 
demonstrated the beneficial effects of anti-IL-5 in patients 
with refractory polyposis and of omalizumab in patients with 
polyposis and severe asthma.47 No studies have yet directly 




impact of reslizumab on asthmatic patient outcomes
compared the effects of reslizumab on nasal polyposis with 
that of other anti-IL-5 or omalizumab, and so specific studies 
are required to identify the most suitable first-choice treat-
ment in this respect.
Is there a need for new data? 
The introduction of specific biological therapies, such as 
anti-IgE and anti-IL-5 antibody treatments, at Step 5 of the 
GINA guidelines has opened a new era of precision medicine 
in asthma since these agents targeted specific severe asthma 
pathways, either allergic or eosinophilic.48 The IL-5 neutral-
izing antibodies mepolizumab and reslizumab were licensed 
in the USA and Europe following successful Phase III studies 
that demonstrated reduced asthma exacerbations frequency 
and improved baseline airflow obstruction27,49 in patients with 
high blood eosinophil levels. Another immunomodulator 
that mediates the effect of IL-5 is benralizumab, an antibody 
directed against IL-5Rα, which showed beneficial effects on 
exacerbations and lung function, particularly in those with 
increased blood eosinophil count.50 Unfortunately, currently, 
we do not have a comparative study of these biological 
therapies in terms of effectiveness and tolerability. A recent 
Cochrane meta-analysis51 including 13 studies on 6000 
participants (4 with mepolizumab, 4 with reslizumab, and 5 
with benralizumab) supports the use of anti-IL-5 treatments 
as an adjunct to standard therapies in patients with severe 
eosinophilic asthma and poor control on the basis that these 
treatments roughly halve the rate of asthma exacerbations in 
this population. However, the authors concluded that there is 
limited evidence for improved HRQoL scores and lung func-
tion in patients treated by anti-IL-5. The safety profile of anti-
IL-5 treatment is acceptable since and high rate of serious 
adverse events has not been registered. In this meta-analysis, 
the number of adverse events leading to discontinuation 
with mepolizumab or reslizumab was similar to placebo, but 
significantly higher compared to placebo when benralizumab 
was interrupted (36/1599 benralizumab vs 9/998 placebo). 
A possible explanation may be that mepolizumab and 
reslizumab markedly decrease blood eosinophils but a small 
number remains, whereas benralizumab almost completely 
deplete the eosinophils. The implications for efficacy and/
or adverse events are still unclear, although benralizumab 
data are intriguing.51 Some relevant results are also available 
on dupilumab. This mAb is directed against the α-subunit 
of IL-4 receptor that can block signaling from IL-4 and 
IL-13. It is shown that dupilumab given subcutaneously can 
increase lung function and reduce severe exacerbations in 
patients with uncontrolled persistent asthma, even in patients 
with low blood eosinophil levels. The transient increase of 
blood eosinophil during the treatment with this drug needs 
to be further investigated.52 Post-licensing real-life studies 
are needed to establish the effectiveness and tolerability of 
these therapies, their optimal duration, long-term benefits 
and adverse effects, risk of relapse on withdrawal, and the 
effect in non-eosinophilic patients and children (particularly 
under 12 years). The comparison of various anti-IL-5 treat-
ments with anti-immunoglobulin E (omalizumab) in patients 
eligible for both is needed. For benralizumab, future studies 
should be undertaken to establish the rates of adverse events 
prompting discontinuation.51,53 In the new era of precision 
medicine in severe asthma, there is an increasing need for 
developing biomarkers that will guide clinicians in the man-
agement of asthma. For the clinician to understand how to 
select the right therapy for the right patient, we also need 
more phenotypic and predictive biomarkers for assessing 
the treatment response. For anti-IL-5 therapies, we probably 
need to look beyond elevated blood eosinophil counts as a 
predictive factor.
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